Diabetic Macular Edema - Pipeline Review, H2 2016

Date: July 20, 2016
Pages: 195
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D0CEF24F89EEN
Leaflet:

Download PDF Leaflet

Diabetic Macular Edema - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Diabetic Macular Edema - Pipeline Review, H2 2016’, provides an overview of the Diabetic Macular Edema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema
  • The report reviews pipeline therapeutics for Diabetic Macular Edema by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Diabetic Macular Edema therapeutics and enlists all their major and minor projects
  • The report assesses Diabetic Macular Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Diabetic Macular Edema
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Macular Edema
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Diabetic Macular Edema pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Diabetic Macular Edema Overview
Therapeutics Development
Pipeline Products for Diabetic Macular Edema - Overview
Pipeline Products for Diabetic Macular Edema - Comparative Analysis
Diabetic Macular Edema - Therapeutics under Development by Companies
Diabetic Macular Edema - Therapeutics under Investigation by Universities/Institutes
Diabetic Macular Edema - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Diabetic Macular Edema - Products under Development by Companies
Diabetic Macular Edema - Products under Investigation by Universities/Institutes
Diabetic Macular Edema - Companies Involved in Therapeutics Development
Aciont Inc.
ActiveSite Pharmaceuticals, Inc.
Adverum Biotechnologies, Inc.
Aerpio Therapeutics, Inc.
Allergan Plc
Ampio Pharmaceuticals, Inc.
Araim Pharmaceuticals, Inc.
Astellas Pharma Inc.
Boehringer Ingelheim GmbH
Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
Clonz Biotech Private Limited
7 COHERUS BIOSCIENCES, INC.
EyeGate Pharmaceuticals, Inc.
EyeGene, Inc.
F. Hoffmann-La Roche Ltd.
Formycon AG
Genmab A/S
Icon Bioscience, Inc.
Kala Pharmaceuticals, Inc.
Kalvista Pharmaceuticals Ltd
Kowa Company, Ltd.
Mabion SA
NicOx S.A.
Oculis ehf
Ohr Pharmaceutical Inc.
Pfizer Inc.
Precision Ocular Ltd
pSivida Corp.
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
SciFluor Life Sciences, LLC
Senju Pharmaceutical Co., Ltd.
Stealth BioTherapeutics Inc.
Sucampo Pharmaceuticals, Inc.
ThromboGenics NV
Verseon Corporation
Xbrane Biopharma AB
Diabetic Macular Edema - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(aflibercept + nesvacumab) - Drug Profile
abicipar pegol - Drug Profile
ACX-107 - Drug Profile
aflibercept biosimilar - Drug Profile
AKB-9778 - Drug Profile
ALG-1001 - Drug Profile
Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile
ASP-440 - Drug Profile
ASP-8232 - Drug Profile
ASPPDC-010 - Drug Profile
AVA-101 - Drug Profile
BI-1026706 - Drug Profile
Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile
cibinetide - Drug Profile
conbercept - Drug Profile
danazol - Drug Profile
dexamethasone acetate - Drug Profile
dexamethasone acetate - Drug Profile
dexamethasone dipropionate - Drug Profile
dexamethasone dipropionate XR - Drug Profile
difluprednate - Drug Profile
Drug for Diabetic Macular Edema - Drug Profile
Drugs for Retinal Diseases - Drug Profile
EBI-031 - Drug Profile
EG-Mirotin - Drug Profile
elamipretide - Drug Profile
fluocinolone acetonide SR - Drug Profile
JDE-006 - Drug Profile
KVD-001 - Drug Profile
loteprednol etabonate - Drug Profile
NCX-422 - Drug Profile
NCX-434 - Drug Profile
NM-108 - Drug Profile
OLX-303 - Drug Profile
PF-655 - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
ranibizumab biosimilar - Drug Profile
RC-1 Alpha - Drug Profile
ripasudil - Drug Profile
RTU-1096 - Drug Profile
SF-0166 - Drug Profile
Small Molecule for Diabetic Macular Edema - Drug Profile
Small Molecule to Inhibit Kallikrein for Diabetic Macular Edema - Drug Profile
Small Molecule to Inhibit LP-PLA2 for Diabetic Macular Edema - Drug Profile
Small Molecules to Inhibit Plasma Kallikrein for DME and HAE - Drug Profile
squalamine lactate - Drug Profile
teprotumumab - Drug Profile
TG-931 - Drug Profile
THR-149 - Drug Profile
triamcinolone acetonide - Drug Profile
VA-999272 - Drug Profile
Diabetic Macular Edema - Dormant Projects
Diabetic Macular Edema - Discontinued Products
Diabetic Macular Edema - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Diabetic Macular Edema, H2 2016
Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Diabetic Macular Edema - Pipeline by Aciont Inc., H2 2016
Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals, Inc., H2 2016
Diabetic Macular Edema - Pipeline by Adverum Biotechnologies, Inc., H2 2016
Diabetic Macular Edema - Pipeline by Aerpio Therapeutics, Inc., H2 2016
Diabetic Macular Edema - Pipeline by Allergan Plc, H2 2016
Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals, Inc., H2 2016
Diabetic Macular Edema - Pipeline by Astellas Pharma Inc., H2 2016
Diabetic Macular Edema - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co., Ltd., H2 2016
Diabetic Macular Edema - Pipeline by Clonz Biotech Private Limited, H2 2016
Diabetic Macular Edema - Pipeline by Coherus BioSciences, Inc., H2 2016
Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals, Inc., H2 2016
Diabetic Macular Edema - Pipeline by EyeGene, Inc., H2 2016
Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Diabetic Macular Edema - Pipeline by Formycon AG, H2 2016
Diabetic Macular Edema - Pipeline by Genmab A/S, H2 2016
Diabetic Macular Edema - Pipeline by Icon Bioscience, Inc., H2 2016
Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals, Inc., H2 2016
Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Ltd, H2 2016
Diabetic Macular Edema - Pipeline by Kowa Company, Ltd., H2 2016
Diabetic Macular Edema - Pipeline by Mabion SA, H2 2016
Diabetic Macular Edema - Pipeline by NicOx S.A., H2 2016
Diabetic Macular Edema - Pipeline by Oculis ehf, H2 2016
Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc., H2 2016
Diabetic Macular Edema - Pipeline by Pfizer Inc., H2 2016
Diabetic Macular Edema - Pipeline by Precision Ocular Ltd, H2 2016
Diabetic Macular Edema - Pipeline by pSivida Corp., H2 2016
Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2016
Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
Diabetic Macular Edema - Pipeline by SciFluor Life Sciences, LLC, H2 2016
Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016
Diabetic Macular Edema - Pipeline by Stealth BioTherapeutics Inc., H2 2016
Diabetic Macular Edema - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
Diabetic Macular Edema - Pipeline by ThromboGenics NV, H2 2016
Diabetic Macular Edema - Pipeline by Verseon Corporation, H2 2016
Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Diabetic Macular Edema - Dormant Projects, H2 2016
Diabetic Macular Edema - Dormant Projects (Contd..1), H2 2016
Diabetic Macular Edema - Dormant Projects (Contd..2), H2 2016
Diabetic Macular Edema - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Diabetic Macular Edema, H2 2016
Number of Products under Development for Diabetic Macular Edema - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Aciont Inc.
ActiveSite Pharmaceuticals, Inc.
Adverum Biotechnologies, Inc.
Aerpio Therapeutics, Inc.
Allergan Plc
Ampio Pharmaceuticals, Inc.
Araim Pharmaceuticals, Inc.
Astellas Pharma Inc.
Boehringer Ingelheim GmbH
Chengdu Kanghong Pharmaceuticals Group Co., Ltd.
Clonz Biotech Private Limited
7 Coherus BioSciences, Inc.
EyeGate Pharmaceuticals, Inc.
EyeGene, Inc.
F. Hoffmann-La Roche Ltd.
Formycon AG
Genmab A/S
Icon Bioscience, Inc.
Kala Pharmaceuticals, Inc.
Kalvista Pharmaceuticals Ltd
Kowa Company, Ltd.
Mabion SA
NicOx S.A.
Oculis ehf
Ohr Pharmaceutical Inc.
Pfizer Inc.
Precision Ocular Ltd
pSivida Corp.
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
SciFluor Life Sciences, LLC
Senju Pharmaceutical Co., Ltd.
Stealth BioTherapeutics Inc.
Sucampo Pharmaceuticals, Inc.
ThromboGenics NV
Verseon Corporation
Xbrane Biopharma AB
Skip to top


Macular Edema - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 63 pages

Ask Your Question

Diabetic Macular Edema - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: